TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Health...(rended toward statistical significance o...),Health
rended toward statistical significance on reduction in spontaneous pain. In addition, a statistically significant pain-reducing effect was observed for the 150 mg dose through 4.5 hours post-dosing.
NGX426 was well tolerated and all subjects completed the three treatment periods. There were no serious or medically important adverse events or changes on laboratory or ECG parameters. The most common adverse events associated with NGX426 administration were mild somnolence and dizziness.
"We are very encouraged by these results that show an analgesic effect for NGX426 in this well-accepted pain model," said Ev Graham, Chief Executive Officer of TorreyPines. "As an oral, non-opioid pain agent, NGX426 could address the significant and documented unmet needs in treating a range of chronic pain conditions including neuropathic pain and acute or prophylactic treatment of migraine. These data, as well as data from our on-going Phase I multiple dose trial, will help us structure our Phase II development plan for NGX426."
NGX426, an ester prodrug, is an oral form of tezampanel, TorreyPines most advanced product candidate. Pharmacokinetic analyses from two Phase I studies confirmed that when given to humans, NGX426 is rapidly converted to tezampanel, the active moiety. Six Phase II, double-blind, placebo-controlled trials have demonstrated that tezampanel, administered either subcutaneously or intravenously, was more effective than placebo in relieving pain across migraine, nociceptive and neuropathic pain models, including a capsaicin-induced pain model.
In order to pursue the Phase II clinical development of NGX426 TorreyPines intends to explore both strategic and financing initiatives.
About TorreyPines Therapeutics, Inc.
TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to
providing patients with better alternatives to existing therapies through
'/>"/>
| SOURCE TorreyPines Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results
2. TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments
3. TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
4. Gamma Secretase Modulators Show Promise in Alzheimers Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
5. TorreyPines Therapeutics to Present at BMO Capital Markets Focus on Healthcare Conference
6. TorreyPines Therapeutics to Present at the JMP Securities Healthcare Focus Conference
7. Heart Failure Patients With Normal Left Ventricular Ejection Fraction Dont Benefit From Treatment With Angiotensin II Receptor Blocker
8. Estrogen and progesterone receptor isoforms expression in the stomach of Mongolian gerbils
9. A new Eph receptor tyrosine kinase overexpressed in gastric cancer was found
10. Researchers create first model for retina receptors
11. Turned-off cannabinoid receptor turns on colorectal tumor growth
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |